The ICD-10-CM code for pancreatic cancer depends primarily on the documented location of the malignant tumor within the pancreas. C25.9 — Malignant neoplasm of pancreas, undetermined may be used if the place is not documented. However, coders should report a more precise C25 code when the pancreatic location is documented by the provider.
Documentation of metastatic illness, treatment contacts, cancer-related discomfort, biliary obstruction, diabetes, or history of malignancy can further complicate pancreatic cancer coding.” Diagnosis coding is critical for billing teams. Diagnosis coding has an impact, on medical necessity claim processing, risk adjustment, authorization and payer coverage.
This practical guide covers pancreatic cancer diagnosis codes, commonly reported CPT and HCPCS services, documentation requirements, and practical medical billing considerations.
What Is the ICD-10 Code for Pancreatic Cancer?
The main ICD-10-CM code, for cancer that starts in the pancreas is C25. The exact code that is used should depend on the part of the pancreas that the doctor says is affected.
| Condition or Scenario | ICD-10-CM Code | Official Description |
|---|---|---|
| Pancreatic head cancer | C25.0 | Malignant neoplasm of head of pancreas |
| Pancreatic body cancer | C25.1 | Malignant neoplasm of body of pancreas |
| Pancreatic tail cancer | C25.2 | Malignant neoplasm of tail of pancreas |
| Pancreatic duct cancer | C25.3 | Malignant neoplasm of pancreatic duct |
| Endocrine pancreatic cancer | C25.4 | Malignant neoplasm of endocrine pancreas |
| Other specified pancreatic site | C25.7 | Malignant neoplasm of other parts of pancreas |
| Overlapping pancreatic sites | C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| Site not documented | C25.9 | Malignant neoplasm of pancreas, unspecified |
CMS materials currently list these C25 codes for pancreatic malignancy.
Why C25.9 Is Not Always the Best Choice
C25.9 is appropriate when the pancreatic site truly remains unspecified in the documentation. It should not replace a more specific code when the medical record clearly identifies the tumor as being in the head, body, tail, pancreatic duct, or another specified part.
For example, if the oncologist documents “adenocarcinoma of the pancreatic head,” C25.0 is more specific than C25.9.
The coder should code from provider documentation and should not independently determine the primary tumor site from an imaging report when the applicable coding rules require provider documentation.
Common Secondary and Related Diagnosis Codes
Pancreatic cancer patients frequently have additional diagnoses that may be relevant to the encounter. These codes should be reported only when supported by documentation and when they meet applicable reporting and sequencing requirements.
| Clinical Scenario | Common ICD-10-CM Code | Description |
|---|---|---|
| Secondary malignant neoplasm of liver | C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| Secondary malignant neoplasm of retroperitoneum/peritoneum | C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
| Secondary malignant neoplasm of intra-abdominal lymph nodes | C77.2 | Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes |
| Encounter for chemotherapy | Z51.11 | Encounter for antineoplastic chemotherapy |
| Encounter for palliative care | Z51.5 | Encounter for palliative care |
| Neoplasm-related pain | G89.3 | Neoplasm-related pain |
| Personal history of malignant neoplasm of pancreas | Z85.07 | Personal history of malignant neoplasm of pancreas |
| Jaundice | R17 | Unspecified jaundice |
| Abnormal weight loss | R63.4 | Abnormal weight loss |
The presence of a metastatic site does not replace the primary pancreatic malignancy code when the primary cancer remains relevant to the encounter. Sequencing depends on the reason for the encounter and the applicable ICD-10-CM guidelines.
The FY2026 Official Guidelines specifically address neoplasm coding, including current versus historical malignancy, secondary sites, sequencing, pain management, and encounters associated with cancer.
How to Select the Correct Pancreatic Cancer Code
1. Start With the Provider’s Diagnosis
Begin with the physician, nurse practitioner, physician assistant, or other qualified provider’s documented diagnosis.
Look for terminology such as:
- Pancreatic adenocarcinoma
- Malignant neoplasm of pancreatic head
- Cancer of pancreatic body
- Malignancy of pancreatic tail
- Pancreatic duct carcinoma
- Metastatic pancreatic cancer
Do not assume that an abnormal imaging finding automatically establishes a definitive malignancy diagnosis.
2. Identify the Exact Pancreatic Site
The C25 category provides several anatomical choices. Documentation should establish whether the malignancy involves the head, body, tail, pancreatic duct, endocrine pancreas, another specified part, or overlapping sites.
If the record simply states “pancreatic cancer” without a documented location, C25.9 may be appropriate.
3. Determine Whether Metastatic Disease Is Documented
Pancreatic cancer can metastasize to the liver , peritoneum , or lymph nodes . When secondary malignancies are identified, the correct secondary neoplasm codes can be submitted together with the main pancreatic cancer diagnosis.
Do not infer metastasis merely because a lesion appears suspicious on imaging. Follow the applicable coding guidelines and provider documentation requirements.
4. Determine the Reason for the Encounter
The same patient may have different principal or first-listed diagnoses depending on why the patient is being treated.
For example:
- Active cancer treatment may involve Z51.11 for an encounter for chemotherapy, subject to sequencing rules.
- A palliative-care encounter may involve Z51.5.
- An encounter specifically addressing cancer-related pain may require G89.3 with the applicable malignancy coding.
- Follow-up after completed treatment may require different coding from an encounter for active malignancy.
This distinction is especially important when claims are submitted for oncology services.
5. Distinguish Active Cancer From Personal History
Do not automatically continue reporting C25 codes indefinitely after treatment has been completed.
When the malignancy has been eradicated and is no longer receiving treatment or being evaluated as an active disease, history coding may become appropriate. The ICD-10-CM guidelines distinguish current malignancy from personal history of malignancy.
CPT and HCPCS Codes Commonly Associated With Pancreatic Cancer Billing
There is not a single CPT code for pancreatic cancer. CPT codes defines services and procedures, while ICD-10-CM codes describe diagnoses.
Depending on the patient’s treatment plan, pancreatic cancer claims may involve services like diagnostic endoscopy, biopsy, surgery, pathology, chemotherapy administration, imaging, and laboratory testing.
Common examples include:
| Service | Common CPT/HCPCS Examples | Billing Consideration |
|---|---|---|
| EUS-related evaluation/biopsy | 43238 | Used for certain EUS-guided tissue sampling services; verify the exact service performed |
| ERCP services | 43274 and related ERCP codes | Code according to the specific endoscopic service performed |
| Pancreatic surgery | 48140, 48145, 48150 and related codes | Select according to the actual pancreatic resection performed |
| Surgical pathology | 88305 and other pathology codes | Depends on specimen and pathology service |
| IV chemotherapy administration | 96413, 96415, 96417 | Administration coding depends on sequence, duration, and drug |
| Additional IV drug administration | 96375, when applicable | Follow infusion hierarchy and payer rules |
| Blood collection/laboratory testing | Examples include 36415, 85025 | Report based on services actually performed |
| Chemotherapy drugs | HCPCS J-codes | Units must correspond to the drug administered and applicable HCPCS descriptor |
CMS guidance emphasizes documenting actual infusion times when time-based chemotherapy administration codes are reported. For example, CPT 96415 is used for qualifying additional chemotherapy infusion time beyond the initial hour, subject to the CPT and Medicare reporting rules.
Oncology billing includes HCPCS medication codes such as J9201 for gemcitabine, J9263 for oxaliplatin, and J9190 for fluorouracil. The actual medication provided and the associated HCPCS code set must support the drug selection and dosage.
NOTE: This is not a complete list of CPT or HCPCS codes. The correct operation, pathology, drug, administration and imaging codes are based on the service actually performed. Coders should check current CPT, HCPCS, NCCI, CMS and payer-specific guidelines before submitting claims.
Documentation Checklist for Pancreatic Cancer Coding
Strong documentation helps coders select the most specific diagnosis and helps billing teams support medical necessity.
| Documentation Element | What the Record Should Clarify |
|---|---|
| Cancer diagnosis | Confirmed malignancy and provider’s diagnostic terminology |
| Primary site | Head, body, tail, duct, endocrine pancreas, other, or overlapping site |
| Histology | When clinically and coding-relevant, such as adenocarcinoma or neuroendocrine tumor |
| Metastatic disease | Documented secondary sites |
| Treatment status | Active treatment, surveillance, remission/history, or recurrence |
| Reason for encounter | Treatment, surgery, chemotherapy, evaluation, pain management, etc. |
| Complications | Jaundice, obstruction, pain, nutritional issues, or other documented conditions |
| Procedures | Exact diagnostic or therapeutic procedure performed |
| Chemotherapy | Drug, dosage, route, start/stop times, and administration details when applicable |
Good documentation also reduces the risk of choosing an unspecified diagnosis when the provider has actually documented greater specificity.
Pancreatic Cancer Coding and Medical Billing: Common Errors
Several coding problems repeatedly create avoidable claim issues:
Using C25.9 when a specific pancreatic site is documented.
Review the provider’s diagnosis before defaulting to unspecified pancreatic cancer.
Treating an imaging finding as a definitive diagnosis.
Coders should follow the applicable ICD-10-CM rules rather than independently diagnosing malignancy.
Confusing primary cancer with metastatic cancer.
A secondary liver or peritoneal malignancy is not interchangeable with the primary pancreatic malignancy.
Reporting active cancer after treatment without reviewing the record.
Determine whether the malignancy remains current or should be reported as a personal history.
Separately billing every infusion component.
Chemotherapy administration follows specific CPT sequencing and hierarchy rules. CMS guidance also addresses when hydration or additional administration services are separately reportable.
Ignoring payer-specific medical necessity requirements.
A diagnosis code can be valid but still fail to satisfy a particular payer’s coverage policy for a service.
Conclusion
ICD-10 code for pancreatic cancer isn’t always just C25.9. To code pancreatic cancer accurately, the billing team needs to identify the reported pancreatic site, decide if there is metastatic disease or comorbidities, differentiate active malignancy from personal history, and define the actual purpose for the contact.
Providers, coders and medical billing teams may make the strongest claims based on detailed provider documentation, correct ICD-10-CM sequencing, accurate CPT/HCPCS reporting and payer-specific medical-necessity standards. Always validate the code set for date of service and check the current official ICD-10-CM, CPT, HCPCS, CMS and payer instructions before submitting the final claim. CMS certifies that ICD-10-CM for FY 2027 will go into effect October 1, 2026. The annual code-set shift is a time when date-of-service verification is especially crucial.
Frequently Asked Questions
What is the ICD-10 code for pancreatic cancer?
The ICD-10-CM category is C25. If the pancreatic site is not specified, C25.9 — Malignant neoplasm of pancreas, unspecified is used when supported by the documentation. More specific codes include C25.0 for the head, C25.1 for the body, and C25.2 for the tail.
What is the ICD-10 code for pancreatic head cancer?
C25.0 — Malignant neoplasm of head of pancreas.
What is the ICD-10 code for pancreatic tail cancer?
C25.2 — Malignant neoplasm of tail of pancreas.
What is the ICD-10 code for pancreatic cancer with liver metastasis?
The primary pancreatic cancer should be coded according to its documented pancreatic site, with C78.7 — Secondary malignant neoplasm of liver and intrahepatic bile duct used when liver metastasis is documented and reportable.
What is the ICD-10 code for chemotherapy for pancreatic cancer?
For an encounter specifically for antineoplastic chemotherapy, Z51.11 — Encounter for antineoplastic chemotherapy is a commonly relevant code, with sequencing determined by the applicable coding guidelines and circumstances of the encounter.